Get a free quote now.
Cancer Treatment Response
The “treatment response of a patient” is the medical term for whether a certain cancer therapy is yielding the desired beneficial results for the patient or not. It is in beneficial for all parties involved when this can be correctly predicted as soon as possible after the therapy has started.
It has been shown that “tissue permeability” can be a great indicator, or "biomarker", for determining if a cancer therapy is working or not. In short: aggressive growing tumoral tissue makes many “mistakes” in producing cells. This causes this tissue to have much higher blood leakage than healthy tissue.
Hyperfusion developed products that not only compares these biomarkers over time, but does so in a 100% automatic manner (*). Hyperfusion integrates into standard hospital infrastructure with reliable and fast processing in the cloud.
Hyperfusion Liver *
Hyperfusion provides 100% automatic cancer treatment response of hepatic tumors.
Hyperfusion Lung *
Hyperfusion provides 100% automatic cancer treatment response of lung tumors.
(*) In clinical evaluation, awaiting CE and FDA approval
Benefits for patient
- Better and faster feedback
- Improved patient outcomes as the patient can change treatment early on
- Avoid unnecessary harm to the patient
Reduced healthcare costs for hospitals, insurance companies, and governments
- Cost of ineffective treatment is ± 1000 EUR per week
- Cheaper CT machines can be used vs. expensive MRI/PET scans
Benefits for pharmaceutical companies / CROs
Normal drug development process of 10-12 years can be significantly reduced in time
Average R&D costs for human clinical trials range between 500M EUR and 2.000M EUR and can decreased considerably.
The patient goes in for a baseline scan before the treatment starts. After the treatment, the patient returns, undergoes a DCE-CT scan and the data is compared with the baseline scan. All steps are 100% automatic and thus no manual intervention is required.